Introduction: Quality and Safety in Ophthalmic Preparations

Ophthalmic drug products are applied into eyes, whether eye drops, intraocular injections, or ointments they must meet the highest quality standards to protect patients’ vision and health. Even tiny contaminants or defects can irritate the eye or cause serious injury. Global regulatory agencies therefore require that ophthalmic preparations be essentially free of visible particulates and sterile. In practice, this means each unit (bottle, vial, ampoule, tube, etc.) is inspected for any foreign particles or flaws, and any that show visible debris must be rejected. Regulators like the U.S. FDA, European EMA, Japan’s PMDA, India’s CDSCO, and the WHO all share this fundamental expectation of “no visible particles” in sterile ophthalmic products. Achieving this high bar consistently is challenging – it demands robust manufacturing controls, thorough visual inspection, and ongoing training of inspectors using tools such as Knapp kits.

A recent FDA guidance underscores that simply passing a compendial particulate test is not enough; manufacturers need a holistic, risk-based approach to control particulates through product design, process controls, and rigorous inspection programs. In ophthalmic manufacturing, this effort is complicated by the variety of packaging formats (from single-dose blow-fill-seal units to multi-dose bottles and ointment tubes) and formulations (clear solutions, protein-based biologics, suspensions, etc.). Each has unique challenges for ensuring particulate-free, defect-free products. This article explores how Knapp kits – specialized sets of test containers with known defects – support ophthalmic product manufacturers in meeting global quality standards. We’ll compare blow-fill-seal (BFS) technology vs. traditional fill-finish methods, cover unit-dose vs. multi-dose formats (and preservative-free vs. preserved products), and highlight regulatory guidelines from the FDA, EMA, WHO, and others. The goal is to provide a comprehensive, human-centered view on achieving ophthalmic product quality using modern visual inspection practices.

Ophthalmic Packaging Formats: BFS vs. Traditional Fill-Finish

Ophthalmic drugs come in several packaging formats, each with its own manufacturing method and quality considerations:

• Single-Dose Units of Blow-Fill-Seal (BFS) – BFS technology forms a plastic container (often polypropylene) from resin, aseptically fills it with solution, and seals it – all in one continuous machine process. BFS is widely used for unit-dose eye drop vials and sterile ophthalmic solutions intended for one-time use (e.g. preservative-free artificial tears). Because the container is formed and filled in a closed system within seconds, there is minimal exposure to the environment. This inherently yields fewer particulates and contaminants compared to traditional methods. Blow Fill seal processes will complete in few seconds generally 3-15 seconds which avoids particle contamination sources during glass vial filling, vial transport, washing or human intervention. BFS single-dose vials also eliminate the need for preservatives, as each sterile unit is meant for one-time use only.
• Eye Drops for Multi-Dose – These are the well-known squeeze bottles (5–15 Gms) with narrow dropper tips, used for prescription and OTC eye drops that patients use over a period of days or weeks. Traditional multi-dose bottles are usually made of inert plastic (or rarely glass) and contain preservatives to prevent microbial growth during use. Manufacturing involves conventional aseptic filling on a production line, the bottles (and sometimes separate droppers/caps) are sterilized, filled with sterile filtered solution, and capped. Because the bottle will be opened repeatedly by the patient, a preservative such as benzalkonium chloride is added to prevent and microbial growth introduced when opened. While preservatives protect against microbes, they do not mitigate particulate matter, any foreign particle in the solution still poses a serious risk to the eye. Thus, multi-dose ophthalmic solutions must be essentially free of visible particulates and must meet strict subvisible particle limits. (In fact, USP <789> “Particulate Matter in Ophthalmic Solutions” applies to all ophthalmic solutions, preserved or not.) Manufacturers of multi-dose drops face the challenge of controlling particulates despite more open handling steps (filling, stoppering) than BFS.
• Semi solid preparation of Ophthalmic Ointments and Gels – Some ophthalmic preparations are formulated as ointments or gels (for example, antibiotic eye ointments). These products are filled into metal or laminate tubes with a narrow applicator tip. The fill-finish process which is similar to semisolid filling but carried out in an aseptic environment for sterile ophthalmic ointments. During this process metal tubes can potentially shed metal particles (from crimping the tube seal) or rubber from caps. Therefore particulate control is critical for ophthalmic ointments are gels. Furthermore, ointments being viscous may hide particles. Global regulatory agencies and pharmacopoeias require ophthalmic ointments to be sterile and “essentially free” of foreign particles just like solutions. In practice, this means raw materials are highly refined, and the final product may be tested by spreading on glass to look for grit or fibers. Ointment packaging is typically multi-use and may contain preservatives as well, although the risk of microbial ingress is lower due to viscosity.

BFS vs. Traditional – BFS single-dose units offer significant contamination control advantages – fewer particles and no risk of glass shards (unlike glass ampoules), as noted by industry experts. BFS is considered an advanced aseptic process (even highlighted by FDA and EMA as an innovative technology) and is often the method of choice for preservative-free sterile eye drops. However, BFS’s plastic containers are less optically transparent than glass, which actually makes visual inspection more challenging. The translucent polypropylene can obscure very small particles. As we’ll discuss later, the threshold for detecting a particle in BFS can be higher (i.e. a particle must be slightly larger to be seen) compared to a crystal-clear glass vial. Traditional fill-finish in glass vials or bottles allows excellent visibility, but comes with higher particulate risk during manufacturing and risks like glass breakage or delamination. Each format requires tailored inspection techniques and training to ensure no defective unit slips through to the patient.

Particulate Matter: Risks in Clear Solutions vs. Protein Formulations

Virtually all ophthalmic products are inspected visually to ensure they contain no visible particulates or defects. But what exactly are inspectors looking for? And how do product formulation differences affect inspection? Key types of particulates/defects include:

• Extrinsic foreign particles: These are contaminants that don’t belong in the product – for example, bits of fiber (e.g. from clothing or packaging materials), dust, hair, metal shavings from equipment, glass or plastic fragments from the container, or other environmental debris. These are highly undesirable and are considered critical defects – any such visible particle means the unit must be rejected. In ophthalmics, a common extrinsic particle might be a fiber or lint, or a speck of dust. BFS processes greatly reduce such extrinsic particulates by operating in closed systems, but they can still occur (e.g. a piece of charred plastic from the BFS molding, or gasket material from machinery).
• Intrinsic particles (product-related): These are particles that originate from the product formulation itself. In the case of ophthalmic solutions, ideally there should be none – a well-formulated solution remains clear. However, sometimes the drug can precipitate or crystallize, forming visible flakes or crystals (for instance, if the solution’s pH or temperature shifts). In ophthalmic suspensions, the drug is intentionally present as solid microparticles (e.g. steroid eye suspensions), so those are “inherent” particles by design. Inspectors must distinguish between the normal suspended drug vs. any foreign particle; this is tricky and often requires training and controlled lighting. For emulsions (like certain cyclosporine eye drops that are milky), droplets might scatter light and make detection harder. Protein-based biologics used in ophthalmology (for example, intravitreal injections like anti-VEGF drugs) can form aggregates – these are clumps of protein that can range from sub-visible sizes up to visible flakes or gel-like particles. Protein solutions might also have slight opalescence (haze), which is not a discrete particle but can complicate visual inspection. Regulators consider any unexpected visible particle a defect regardless of origin. So if a protein drug vial has a flake of protein aggregate floating, that vial is not “essentially free of particles” and must be rejected, just as if it contained a bit of lint. Manufacturers mitigate intrinsic particles by rigorous formulation development and stability testing – for instance, stress testing ophthalmic suspensions to ensure particles don’t grow or agglomerate over shelf-life. USP <771> Ophthalmic Products—Quality Tests recommends monitoring particle size in suspensions over time.
• Cosmetic and container defects: While not “particles,” other visible defects are checked during inspection as well – e.g. cracks in a vial or bottle, improper seals, air bubbles, fill volume issues, or discoloration. A crack or poor seal is critical because it risks sterility; a major cosmetic defect (like a badly skewed cap or scratched label) might be classified as a lesser defect but still cause rejection under quality standards. BFS containers have some unique potential defects: incomplete seals, plastic flash or burrs at the edges, or occlusions in the tip. Glass containers might have cracks or glass lamellae (thin glass flakes from delamination). Inspectors are trained to spot all these issues, not just particles. Modern Knapp defect kits often include examples of various defect types – not only particulate contamination but also fill-level errors, closure issues, etc., to ensure inspectors can catch the full range of problems.

Opaque vs. Clear Solutions – Visual inspection of clear liquids, like water-based solution in a transparent container is easier when compared to opaque solutions. In these conditions, inspectors can readily detect the particles as dark or white specks against appropriate backgrounds. Most topical eye drops formulations are clear solutions, which is advantageous for visual inspection. However, if the solution contains protein or other colloids, it may not be perfectly clear. Opalescent or foaming solutions reduce visibility. Likewise, suspensions and emulsions used in eye products present a challenge of cloudy or moving dispersed phase, making it harder to discern a foreign particle. Inspectors compensate by careful technique (e.g. swirling and observing for any different particulate movement than the normal suspension) and by using magnification or alternate light techniques if needed. AVI systems frequently struggle with opaque products, sometimes manual inspection is still the fallback for suspensions and viscous products, because a human can better discern context.

Global Regulatory Standards for Visual Inspection of Ophthalmics

Below is summarized key regulatory and pharmacopeial standards that apply:

• United States (FDA & USP) – The USP–NF compendial standards are enforceable by FDA for product release. USP <790> “Visible Particulates in Injections” requires that every lot of injectable drug product be essentially free of visible particles; it specifies that 100% visual inspection of units is to be performed, by manual or automated methods. Any container with visible particles is rejected, and an Acceptable Quality Limit (AQL) sampling of the rest is done as a final verification. Notably, USP <790> assumes ~100 µm as a general lower size limit for visibility (under optimal conditions), but it acknowledges this varies with container, product, and particle characteristics. For ophthalmics, USP <789> “Particulate Matter in Ophthalmic Solutions” lays out the subvisible particle limits, typically not more than 50 particles per mL ≥10 µm, and not more than 5 particles per mL ≥25 µm (for solutions intended for ophthalmic use). These limits are stringent – for example, a 5 mL eye drop bottle can have at most 5×50 = 250 particles ≥10µm in the entire bottle (and practically, good products have far fewer). The USP general chapter <1> on injections also reinforces that injectable (and by extension intraocular and ophthalmic) products should be formulated and filtered to exclude particulate matter. FDA’s Guidance “Inspection of Injectable Products for Visible Particulates” (2022), while focused on injectables, is very relevant to ophthalmic manufacturers. It stresses a life-cycle approach: control particulates at the source (raw materials, components, environment), use proper visual inspection (with adequate lighting, background, and training), and investigate and identify particles when they are found. Importantly, FDA notes that simply passing USP <788>/<789> tests isn’t enough for cGMP – firms should continuously improve and understand their processes to minimize particulate contamination. For ophthalmic products, FDA is the “regulatory anchor” often referencing USP but also applying cGMPs (21 CFR 211) – e.g. 21 CFR 211.94 on container cleanliness, 211.165 on testing, etc. Recent FDA guidance (2023 draft) on ophthalmic products specifically highlights particulate matter as a key quality consideration, citing USP <771> and <789>.
• European Union (EMA & Ph. Eur.) – The European Pharmacopoeia (Ph. Eur.) has similar tests: Ph. Eur. 2.9.20/2.9.21 cover particulate contamination (sub-visible and visible). The general monograph for Parenteral Preparations requires solutions to be “practically free from particles”. The phrase “essentially free from particulates” is used, meaning no visible particles when inspected under suitable conditions. EU GMP guidelines (EudraLex Volume 4, Annex 1 revised 2022) explicitly state that all units of sterile products must undergo 100% visual inspection for container/closure integrity and particulates, unless an alternative method of equivalent sensitivity is in place (e.g. some automatic technologies). Annex 1 also emphasizes inspector qualifications – operators must have regular eye exams and should not inspect for long periods without break. In practice, EU inspectors expect companies to rotate visual inspection staff frequently (guidance suggests sessions of ideally 15–20 minutes of inspecting, followed by a break to rest the eyes). This reduces fatigue and the risk of missing a defect. EU GMP also requires periodic requalification of inspectors (recommendation: at least annually, if not more often) to ensure they maintain detection capability. The use of reference test sets (Knapp kits) for qualification is common in Europe and is aligned with Annex 1 expectations of ongoing training and proficiency testing. Automated inspection machines in EU must undergo thorough validation and still require periodic challenge tests to ensure they consistently detect required defects – Annex 1 calls for both equipment qualification and routine performance monitoring (e.g. using seeded defect kits). In short, Europe’s standards mirror the US in outcome (no visible particles), with additional detail on how to manage the inspection process and personnel.
• WHO and Other Agencies – The World Health Organization, through its GMP guidelines and the Prequalification Programme, also enforces that sterile ophthalmic products be free of visible particulate contamination. WHO’s guidance documents (e.g. WHO Technical Report Series) echo pharmacopoeial standards and often serve as the model for countries where local guidelines are still developing. Manufacturers seeking WHO prequalification of eye products must demonstrate robust visual inspection processes and compliance with pharmacopeial particulate limits. India’s CDSCO (Central Drugs Standard Control Organization) generally aligns with US/EU pharmacopeia for quality requirements; the Indian Pharmacopoeia likewise has tests for particulate matter in injections and ophthalmic solutions that are harmonized with USP/Ph. Eur. as part of global pharmacopeial harmonization. India is now a member country of Pharmaceutical Inspection Co-operation Scheme, Indian GMP expectations for visual inspection program are essentially equivalent to EU GMP Annex 1. Japan’s PMDA relies on the Japanese Pharmacopoeia (JP), which similarly requires no visible foreign matter in injections and ophthalmic products.

AVI systems are increasingly used, including in ophthalmic BFS lines. However, any automated visual inspection system must be proven to be equivalent or better than human inspection in defect detection. This can be demonstrated by performing a Knapp test or similar study for comparing human vs machine performance on a standard defect set. Many firms still perform a final manual AQL sampling after automated inspection, as a check, since human inspectors have different perceptual strengths.

What’s inside a Knapp kit?

Typically, a kit will include a series of sample containers (vials, ampoules, BFS units, etc. depending on the product) that are indistinguishable from normal product units, except some have a known defect seeded in them. For example, a Knapp kit for liquid vials might have: a few vials each containing a particle of a specific size (say one with a ~50 µm fiber, one with a ~100 µm metal shard, one with a ~150 µm glass fragment, etc.), plus some vials with other defects like a crack or low fill, and a number of “good” vials with no defects.

Visual inspection kits are applied in several scenarios:

• Training and qualification of trainee inspectors – Trainees practice with the Knapp kit to learn how particles appear, how to facilitates the container (swirl, invert, view against black/white backgrounds) and to calibrate their eyes to the task. They only “pass” training when they can consistently detect the required defects. These kits provide a standardized challenge that every trainee must overcome, ensuring a baseline competency. As one source put it, these kits build inspector acuity and confidence, reducing human error during 100% inspection. Without such a tool, training would be subjective (“look really carefully”) and it would be hard to know if a new inspector is up to the job.
• Periodic re-qualification of inspectors – Human performance can drift over time – eyesight can change, or complacency can set in. GMP guidelines (like EU Annex 1) expect that inspectors be re-qualified at intervals (e.g. every 6 or 12 months). Surprise Knapp kit tests are a great way to do this: an inspector is given a kit mixed into routine samples at random and is evaluated without prior warning. The results will show if they still catch the defects. If an inspector fails to detect some defects that they ought to, they can be retrained or temporarily removed from inspection duties. Best practice is to perform these tests at the end of a shift or after a long inspection period – a “worst-case” to see if fatigue affects their acuity. This helps set appropriate work/rest cycles as well.
• Qualification of AVI systems – Automated vision machines are also challenged with Knapp kits (sometimes called “defect sets” for machines). The kit might contain vials with particles of known sizes to see if the machine’s camera and software catch them. The Knapp test in a formal sense compares a new inspection method vs. an existing one using such defect sets. Modern AVI systems often tout >90% detection of ≥100 µm particles, which exceeds typical human performance (humans might be ~70–80% at 100 µm under normal conditions). Using Knapp kits, these claims can be verified. In one study, a fully automated system showed a ~97% detection rate and much lower false rejects compared to manual inspection and the Knapp test confirmed it was 103.8% as efficient as the manual baseline, essentially proving it superior.
• Process troubleshooting and ongoing monitoring – Some companies incorporate routine “challenge samples” in each batch inspection – e.g. spiking one particle-containing vial in the lot (removed later) to ensure the inspector or machine on duty is functioning properly. While not always feasible in production (due to strict accounting of units), during setup of a batch or shift it can be done as a sanity check. Knapp kits can also be used to study the limits of detection for a particular product.

Popular and well reputed Knapp kit manufacturing organizations like Nishka Research Pvt Ltd., offer documentation and data of the defects of known sizes which includes magnified image library with size including certified particulates and fibers. These kits are assembled under controlled conditions, usually in clean rooms such as Class 100. This ensures that when an inspector fails to see a particle, it’s truly because of capability and not because the particle wasn’t there or smaller than expected. Kits often come with high-resolution images of the defects and measurement data – though of course the inspector should not see those images until after their test (to avoid bias). Documentation of kit composition is also useful for audits: regulators may ask “how do you know your inspectors can reliably detect 100 µm fibers?” The firm can then show the Knapp kit results and the kit’s specs, demonstrating compliance with USP <1790> recommendations on ongoing inspector performance monitoring. In fact, using Knapp kits is a concrete way to fulfill USP <1790>’s call for a lifecycle approach to visual inspection – training, qualification, requalification, and continuous improvement. By establishing a standardized defect library and detection thresholds, companies control the traditionally subjective process of visual inspection and bring data-driven confidence to it.

Preservative-Free vs. Preserved Products: Impact on Inspection

As mentioned earlier, preservative-free ophthalmic products are usually presented in single-use sterile packaging (often BFS). The move toward preservative-free formulations (to avoid chronic exposure of eyes to preservatives) has been a big trend, especially in Europe. With this comes an even greater emphasis on initial product sterility and cleanliness. In a preserved multi-dose eye drop, if a tiny number of microbes accidentally entered after first use, the preservative might neutralize them. But in a preservative-free unit, any contamination means potential infection. Similarly, any particulate matter in a single-dose could be administered all at once into the eye. Thus, manufacturers of preservative-free ophthalmics tend to adopt tighter internal specs for particulate matter than the bare minimum. For example, while USP <789> allows up to 50 particles/mL ≥10 µm, a company might aim for far lower counts for a preservative-free product, to provide extra safety margin. Furthermore, visual inspection standards may be heightened: inspectors might be instructed to be especially vigilant for even the tiniest fuzz or fiber. In practical terms, the process isn’t different – you still reject anything with a visible particle – but the mindset is one of zero tolerance. Manufacturers also often perform 100% inspection twice (two independent inspectors or one manual plus one automated) for preservative-free lots, whereas perhaps a single automated pass might be considered for a preserved product. This double-inspection ensures any unit with a doubtful appearance is caught.

Preservative-free products also often end up being used in surgical or intraocular situations (e.g. preservative-free lubricants during surgery, or injections). In those cases, particulate stakes are even higher: an intraocular injection that contains a particle could literally float in the patient’s vision or cause an inflammatory reaction inside the eye. Regulators like FDA treat intraocular injections as injections (so USP <788> and <790> fully apply). For example, an intravitreal injection solution must pass USP <788> limits (which for small-volume injections is ≤6000 particles ≥10µm per container) – though in practice they usually have orders of magnitude fewer. Manufacturers of such biologics implement extensive filtration (often 0.2 µm sterilizing filters plus additional 0.1 µm “finishing” filters to reduce subvisible particles) and sometimes manual visual sorting under magnification to eliminate any vial with any hint of particulate. The inspection of proteins and biologics for ophthalmic use may involve additional techniques beyond normal human inspection, such as background illumination to detect opalescence changes or using a polarizer to differentiate protein strands from glass shards. Inspectors receive specialized training to recognize protein aggregates (which can look like translucent wisps or flakes) versus, say, lint fibers. Interestingly, some protein aggregates may not reflect light as well, making them less visible than, say, an opaque dust particle. This is all the more reason that inspection programs for these products are highly robust and often incorporate semi-automated inspection with higher sensitivity cameras (some systems use polarized light imaging to catch protein agglomerates).

Also, multi-dose bottles have an assembly (bottle, dropper plug, cap) – inspectors also check that the dropper plug is properly inserted and that there’s no plastic flash or particles around the bottle neck from the insertion process. Ointment tubes with preservatives are similarly treated – they must be inspected externally (for tube damage) and often a sample of the ointment is tested for particulate contamination using a method like melting or dissolving it and filtering, since you can’t see through the metal tube.

In summary, preservative-free formats demand the highest vigilance: absolutely pristine product because there is no second line of defense. Preserved formats still require the same level of visible particle control (a particle is unacceptable regardless of preservative) but the context of use (multiple dosing, patient handling) and slightly higher volume per unit means inspection processes might adjust (e.g. more headspace in the bottle can help swirl the liquid to see particles, whereas BFS units sometimes have almost no headspace). Regulatory standards for visible particles do not loosen just because a preservative is present – all agencies still mandate no visible particulates in both cases. The presence or absence of preservative mainly affects microbiological testing and labeling requirements, not the particulate specs. Both FDA and EMA have been clear: if a multi-dose product omits preservatives, it must use packaging that prevents contamination and must include warnings in labeling, but from a quality standpoint, every unit must still pass visual inspection and meet USP/Ph.Eur. particulate limits. Thus, from the visual inspection perspective, we emphasize the product’s format (unit vs. multi) and how it’s made (BFS vs traditional) more than the presence of preservative, except to note that preservative-free single-dose manufacturing tends to incorporate even more stringent in-process controls to minimize all contaminants.

Best Practices and Conclusions

Ensuring ophthalmic products are free of particles and defects is a critical aspect of patient safety and regulatory compliance. Even “small” issues can have serious consequences in the eye – for example, a mere dust speck in an eye drop can scratch the cornea, and a contaminated eye solution can cause infection or endophthalmitis. Health authorities around the world recognize this, which is why there is a remarkable convergence of standards: essentially, no visible particulates, minimal subvisible particles, 100% inspection of units, and thorough training of personnel. Key best practices that have emerged from industry experience and guidances include:

• Adopt advanced aseptic technologies where feasible to minimize contamination at the source. Blow-Fill-Seal is one such technology that has proven to reduce particle ingress by limiting open exposure. However, be mindful of the inspection challenges BFS introduces (e.g. container transparency). Leverage specialized inspection setups (such as the vibration-assisted BFS particle inspection systems) to overcome these challenges. For manufacturers sticking with traditional filling, invest in clean environments and processes (e.g. laminar flow protection, component washing) to keep particle loads low before inspection.
• Implement rigorous visual inspection programs that comply with USP <790>/<1790> and EU Annex 1 expectations. This means: use adequate lighting (typically 10,000–15,000 lux) and contrasting backgrounds during inspection]; control inspection time and human factors (rotate inspectors, give breaks every 20 minutes or so to avoid fatigue); and ensure each container is viewed methodically (e.g. following the black/white screen method). Where automated systems are used, validate them thoroughly and maintain them – including routine challenge tests with Knapp kits to ensure they continue to “see” as well as intended.
• Qualify and requalify inspectors and inspection equipment with Knapp kits or certified defect sets. This brings objectivity and consistency to an otherwise subjective process. By using Knapp kits aligned with USP <1790> guidance, companies can demonstrate inspectors’ detection rates and continuously improve training. For example, if a particular type of defect is often missed (say, transparent fibers in a suspension product), that can be analyzed and the training adjusted (maybe add magnification or tweak lighting). Regulators in FDA and EMA audits increasingly ask about how firms ensure their visual inspection is effective – showing data from Knapp kit trials (with a high detection probability and low false reject rate) is a powerful answer, indicating a science-based approach to visual inspection. It assures them that your program is “state of the art” and aligned with global expectations.
• Integrate particulate control into the full product lifecycle. Don’t just rely on end-stage inspection to catch problems – prevent them. This means designing formulations and selecting container materials to minimize particle generation (e.g. use low-shedding dropper tips, pre-washed components, avoid reactive glass that flakes). Implement robust filtration and handling techniques: many ophthalmic solutions are sterile-filtered at 0.2 µm, but using an additional 0.45 µm pre-filter can reduce bioburden and particle load. Monitor your environment – airborne particulates in the filling room should be minimized (Class 100 / ISO 5 conditions typically). Seamless maintenance of equipment’s (lubricants, gaskets) has to be carried out to avoid shredding of particles like metal or rubber and when particles are found during inspection, The comprehensive investigation has to be performed including root cause analysis (RCA) and follow necessary actions to mitigate the reoccurrences (Corrective And Preventive Actions).
• Update with current global standards and guidance. The regulatory landscape is dynamic and changing from time to time with necessary updates. For example, the revised EU Annex 1 (2022) added more detailed requirements on visual inspection, including clearer expectations for qualification and documentation. International organizations (PDA, ISO) also publish technical reports on best practices for visual inspection. Companies should update their SOPs and training to reflect the latest (e.g. adjust inspection criteria if pharmacopeias update particulate limits, or incorporate new tools like automated vision algorithms). Networking with industry groups or forums can provide insight – for instance, PDA’s Visual Inspection Forum often covers case studies of Knapp test implementation, new inspection technology, etc.

In conclusion, ensuring that ophthalmic preparations – be it the smallest eye drop or an intravitreal injection – are free from visible particulates is a non-negotiable aspect of quality. Through a combination of modern manufacturing (like BFS), comprehensive inspection programs, and training tools like Knapp kits, manufacturers can achieve the high bar set by regulators worldwide. The result is not only regulatory compliance and audit readiness, but fundamentally safer products for patients. Visual inspection may seem old-fashioned in this era of automation, but it remains a critical guardian of quality for sterile products. By “deep diving” into each bottle or vial with trained eyes (or lenses), we uphold the trust that when a patient uses an eye drop or a surgeon injects a therapy into the eye, it is pure, safe, and effective – with nothing in it that shouldn’t be there.

FAQ’s: